NCT00496873View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Lymphoma
Interventions
DRUG

Cytoxan

600 mg/m\^2 on Day 1 of 21-day cycle.

DRUG

Nipent

4 mg/m\^2 on Day 1 of 21 Day Cycle.

DRUG

Rituxan

375 mg/m\^2 on Day 1 of 21 Day Cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Pharmatech

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER